# Junta clínica — PT-pseudo_21e7fa67a79e (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_21e7fa67a79e",
  "pid": "PT-pseudo_21e7fa67a79e",
  "task": 1,
  "psa": 11.0,
  "age": 70,
  "months": 3,
  "pirads": "5",
  "psad": 0.108,
  "psav": 2.49,
  "psap": 7.8,
  "vol": 101.95,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.77544403,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 11 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 102 mL. csPCa 0.78.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "100 kg",
    "height": "183 cm",
    "bmi": "29.9",
    "bp": "123/79 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (29 pack-yr, quit 2007)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Feb 2025",
  "enc_ref": "Dr. N. Kuiper (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment of a previously positive prostate biopsy alongside a steadily climbing PSA trajectory."
    },
    {
      "s": "History",
      "t": "First brought to clinical attention for a PSA elevation in late 2022, this 70-year-old gentleman has a previously positive prostate biopsy bucket recording Gleason 3+4 pathology. He endures severe lower urinary tract symptoms, scoring 34 on the IPSS, which heavily disrupts his daily activities despite a lack of prior surgical interventions. A retired postal worker who has never married, he resides alone with his adult daughter acting as primary contact and a longstanding friend listed as next of kin. His lifestyle includes cycling roughly 20 kilometres twice each week and drinking about five alcohol units weekly; he ceased smoking 29 pack-years ago back in 2007. Aside from a right knee arthroscopy in 2018 and a recent practice-nurse-administered influenza vaccine, his medical background remains clear. He explicitly denies unexplained weight loss, bone pain, or haematuria."
    },
    {
      "s": "Physical examination",
      "t": "Normal DRE: The prostate measures symmetrically enlarged, presenting a smooth capsule devoid of palpable nodules or asymmetry. General examination remains unremarkable, characterised by stable vital signs and an absence of systemic illness or lymphadenopathy."
    }
  ],
  "occupation": "retired postal worker",
  "marital": "Never married",
  "living": "Lives alone; adult daughter is primary contact",
  "next_of_kin": "Long-time friend (no close family)",
  "recent_other": [
    "GP practice nurse — flu vaccination"
  ],
  "alcohol": "5 units / week",
  "exercise": "Cycling 2x/week, ~20 km",
  "ipss": "IPSS score: 34/35 (severe LUTS)",
  "admin": "Interpreter: not required. Consent for data use: signed.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_21e7fa67a79e
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 70-year-old male
  - PSA: 11.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.108 ng/mL²
  - PSA velocity: 2.49 ng/mL/yr
  - Prior PSA: 7.8 ng/mL
  - Prostate volume: 101.95 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.77544403 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 11 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 102 mL. csPCa 0.78.

Vitals: weight 100 kg, height 183 cm, BMI 29.9, BP 123/79 mmHg, HR 72 bpm. Smoking: Ex-smoker (29 pack-yr, quit 2007).

Chief complaint: Assessment of a previously positive prostate biopsy alongside a steadily climbing PSA trajectory.

History: First brought to clinical attention for a PSA elevation in late 2022, this 70-year-old gentleman has a previously positive prostate biopsy bucket recording Gleason 3+4 pathology. He endures severe lower urinary tract symptoms, scoring 34 on the IPSS, which heavily disrupts his daily activities despite a lack of prior surgical interventions. A retired postal worker who has never married, he resides alone with his adult daughter acting as primary contact and a longstanding friend listed as next of kin. His lifestyle includes cycling roughly 20 kilometres twice each week and drinking about five alcohol units weekly; he ceased smoking 29 pack-years ago back in 2007. Aside from a right knee arthroscopy in 2018 and a recent practice-nurse-administered influenza vaccine, his medical background remains clear. He explicitly denies unexplained weight loss, bone pain, or haematuria.

Physical examination: Normal DRE: The prostate measures symmetrically enlarged, presenting a smooth capsule devoid of palpable nodules or asymmetry. General examination remains unremarkable, characterised by stable vital signs and an absence of systemic illness or lymphadenopathy.

Patient info: retired postal worker; Never married; Lives alone; adult daughter is primary contact.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 5 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 34/35 (severe LUTS).

Recent other appointments: GP practice nurse — flu vaccination.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.13 epistemic (95% band 0.37-0.89); among patients I cannot tell apart the outcome was 0.95 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = none recorded (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 70 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 11 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 101.95 mL (1% of my signal; from log_vol, vol) · PSA density = 0.108 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.78 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 70 · DRE = Normal · PSA = 11 ng/mL · prostate volume = 101.95 mL · PSA density = 0.108 · PI-RADS = 5 · comorbidity = none recorded
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.12: PI-RADS 5, PSA 5.5, PSAD 0.12, age 71, DRE Normal -> BIOPSY (clear). He wrote: "Prev biopsy finding is left lobe, MRI finding highly suspicious of ISUP≥2 on right side. Active surveillance, only 1 biopsy session performed (of unclear date and unclea…"
  2. distance 1.53: PI-RADS 5, PSA 10.0, PSAD 0.27, age 75, DRE Normal -> BIOPSY (clear). He wrote: "New(? -> no old MRI report included) PIRADS 5 and rising PSA makes biopsy necessary"
  3. distance 1.78: PI-RADS 5, PSA 19.0, PSAD 0.37, age 65, DRE Normal -> DEFER (clear). He wrote: "Patient needs treatment without repeat biopsy as earlier biopsy showed ISUP4"

PRECEDENT: BIOPSY (weighted vote 0.73 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   PI-RADS = 5
  important  prior biopsy = Positive · csPCa probability = 0.78
  noted      family history = not opened (0 of 91) · age = 70 · DRE = Normal · PSA = 11 ng/mL · prostate volume = 101.95 mL · PSA density = 0.108 · comorbidity = none recorded
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 70 · PSA = 11 ng/mL · PI-RADS = 5
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 101.95 mL · PSA density = 0.108 · comorbidity = none recorded
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
"linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20ng/mL) (Table 5.5) [230]. This risk-adapted matrix table may guide the decision to perform a biopsy."
The guideline suggests using a risk-adapted matrix table based on PI-RADS score and PSA density to guide the decision to perform a biopsy. For this patient, the PI-RADS score is 5 and the PSA density is 0.108 ng/mL/cc, which falls into the intermediate-high risk category according to the retrieved data.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I see that you marked prior biopsy as decisive, whereas the guideline treats this as context. The guideline suggests that the PI-RADS score and PSA density are key variables in this decision. The guideline requires the PI-RADS score and PSA density to determine the risk-adapted pathway. The guideline needs the prior grade of the prior biopsy to determine if the patient should proceed to treatment or further tissue sampling.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: at Positive the guideline suggests the decision depends on other factors like PI-RADS and PSA density.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the rising PSA velocity is a factor that the guideline incorporates into the risk assessment.
laboratory_results - the laboratory results: the PSA density is a key variable used in the risk-adapted matrix.
family-history anamnesis - the family history of prostate cancer: the guideline suggests this is a variable that can be used in risk stratification.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the documented prior biopsy grade, found in the previous notes, overrides the current high PI-RADS score and PSA density as suggested by the EAU guideline.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Must state whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Must detail the PSA trend, including the rising PSA velocity.
  previous_notes (get_previous_notes) -> Must state the documented grade of the prior biopsy and surveillance status.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade of the prior biopsy, as detailed in the previous notes?
  Q2. Does the radiology report indicate if the lesion is compared against an earlier study?
  Q3. Does the PSA trend, specifically the rising PSA velocity, influence the decision according to the EAU guideline?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion is compared against an earlier study: new.
LESION: size and zone of the index lesion, as the report words it: "A focal lesion occupies the left peripheral zone at the base/mid-gland level, spanning approximately 28 mm in maximum dimension."

psa_trend
The PSA trend: PSA has risen from 10.2 (Dec 2022) to 11.0 (Feb 2025), with a rising PSA velocity indicated by the trend data.

previous_notes
PRIOR GRADE: not recorded
BIOPSY SESSIONS: not recorded
SURVEILLANCE: not recorded

WHAT I DID NOT OPEN
family-history anamnesis, because the decision hinges on the documented prior biopsy grade and the imaging/PSA trend.

WHAT THIS SUPPORTS
FOR sampling this patient now
radiology_report: PI-RADS 5 lesion in the left peripheral zone, consistent with high probability of clinically significant prostate cancer.
psa_trend: PSA has risen from 10.2 (Dec 2022) to 11.0 (Feb 2025), indicating a rising PSA velocity.

AGAINST sampling this patient now
previous_notes: PRIOR GRADE: not recorded, meaning the current decision relies heavily on the imaging and PSA trend.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 11.00 ng/mL over 4 points spanning 26 months; velocity -0.19 ng/mL per year; no meaningful doubling time.
PROJECTION at 6 months: 24.0 ng/mL, conformal 95% band 6.9-83.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 11 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.14 epistemic (95% band 0.36-0.89), of which 0.01 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 11 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 101.95 mL (4% of my signal; from log_vol, vol) · PSA density = 0.108 (0% of my signal; from psad_calc) · comorbidity = none recorded (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.63  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.63  ('discuss' tier, fusion_nolab; weight 1.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.73  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.63 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_nolab). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          70                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Normal                       E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          11 ng/mL                     E1:not E3:not cohort:not library:not E2:not          -> important
  vol          101.95 mL                    E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.108                        E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.78                         E1:not E3:— cohort:— library:IMP E2:—                -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:DEC E2:—            -> important
  comorbidity  none recorded                E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: borderline.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) have answered the moderator's questions regarding the comparison of the lesion, the PSA trend, and the prior biopsy status.

ALIGNMENT WITH THE PANEL
The retrieved evidence, specifically the rising PSA velocity from the PSA trend and the finding that the prior grade is "not recorded" from the previous notes, aligns with the Panel-Protocol's conclusion that the decision relies on the trained experts because the documented prior grade was missing.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade of the prior biopsy, as detailed in the previous notes? The previous_notes state: "PRIOR GRADE: not recorded".
Q2. Does the radiology report indicate if the lesion is compared against an earlier study? The radiology_report states: "The lesion is compared against an earlier study: new."
Q3. Does the PSA trend, specifically the rising PSA velocity, influence the decision according to the EAU guideline? The psa_trend details that "PSA has risen from 10.2 (Dec 2022) to 11.0 (Feb 2025), with a rising PSA velocity indicated by the trend data."

WHAT CARRIES WEIGHT, AND WHY
psa: important: 11 ng/mL, because it was noted by the panel and is a key variable in the EAU guideline risk matrix.
pirads: important: 5, because it was marked as important by the panel and is a key variable in the EAU guideline risk matrix.
prior biopsy: decisive: Positive, because the panel marked this as decisive, although the notes state the grade is not recorded.
MY SUGGESTION TO THE CHAIR
The record is ready for a decision as all documents listed by the trace model were opened. The panel's answer of BIOPSY rests on the weighted vote of the experts, which is supported by the imaging findings and the rising PSA trend, despite the missing prior biopsy grade.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

70y male, PSA 11.0, PSAD 0.108, PI-RADS 5, prior biopsy grade not recorded. High PI-RADS 5 and rising PSA velocity suggest need for tissue diagnosis. Lack of prior grade mandates biopsy to determine management pathway.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
